NovaBiotics is a leading clinical stage biotechnology company focused on the design and development of first-in-class anti-infective therapies for difficult to treat, poorly served infectious conditions. Our rational drug design approach and unique patented peptide anti-infective technology has already been validated through successful clinical development of the company's lead compound, Novexatin®, a topical (brush on) treatment for fungal nail infections. A robust and exciting pipeline of drug candidates are also being developed for conditions such as life threatening blood stream fungal infections (predominantly candidaemia) and cystic fibrosis.

NovaBiotics has looked to nature as the template for engineering a totally novel class of antimicrobial peptide therapies and believes its patented, proprietary technology has potential to meet the need for safer, more effective antimicrobials and address the various and well described shortcomings of conventional anti-infective therapies. [Read more]

Click here for NovaBiotics' Luminaderm range of cosmetic and healthcare products